Linares Tablet contains Linagliptin 5 mg, a potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for the management of type 2 diabetes mellitus. Linagliptin works by enhancing the levels of incretin hormones, which increase insulin secretion and decrease glucagon release in a glucose-dependent manner, thereby improving glycemic control. This medication is typically prescribed as monotherapy or in combination with other antidiabetic agents such as metformin or sulfonylureas when diet and exercise alone do not provide adequate glycemic control. Linares Tablet is administered orally once daily, with or without food, and is particularly advantageous due to its predominantly non-renal route of elimination, making it suitable for patients with varying degrees of renal impairment without dose adjustment. Clinical studies have demonstrated that Linagliptin effectively lowers HbA1c levels with a low risk of hypoglycemia and a neutral effect on body weight. Common adverse effects may include nasopharyngitis, headache, and upper respiratory tract infections; however, it is generally well tolerated. Patients should be monitored for signs of pancreatitis and hypersensitivity reactions. Linares Tablet should be used under medical supervision as part of a comprehensive diabetes management plan.